Filed with ASX · · 2 pages · English
BTC Health Ltd has announced that its subsidiary, BTC Pharma, has secured exclusive distribution rights for Sativex in Australia and New Zealand. Sativex is a prescription medicine used for treating moderate to severe spasticity due to multiple sclerosis and is one of the few medicinal cannabis products registered in Australia. Under the agreement, BTC Pharma will manage regulatory and commercial activities for Sativex, while CNX Therapeutics will manufacture and supply the product. The agreement has an initial term of five years, with potential for extension, and BTC expects to generate sales from Sativex in the first year of supply.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
BTC Health Limited (BTC) – ASX Announcement 6 November 2026 BTC secures exclusive Australian and New Zealand distribution rights for Sativex® Highlights • BTC Pharma has signed an exclusive distribution agreement with CNX Therapeutics for Sativex® (nabiximols) in Australia and New Zealand •...
BTC Health Ltd Registered on 6ix
Follow BTC Health Ltd Registered into a list and get an email when it puts out news.
Follow BTC Health Ltd Registered